Evidence map›Paper›PMID 40647396›Full record

ReviewCancers2025

Michael D Diamantidis, Maria Smaragdi Vlachou, Anastasia Katsikavela, Smaragdi Kalomoiri, Vasiliki Bartzi, Georgia Ikonomou

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael D DiamantidisThalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece.ORCID 0000-0002-0041-5930
Maria Smaragdi VlachouThalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece.
Anastasia KatsikavelaThalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece.
Smaragdi KalomoiriDepartment of Hematology-Lymphoma, Bone Marrow Transplantation Unit, Evangelismos General Hospital, 10676 Athens, Greece.
Vasiliki BartziFirst Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Georgia IkonomouThalassemia and Sickle Cell Disease Prevention Unit, General Hospital of Larissa, 41221 Larissa, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aberrant localization of the mutated

Indexed as

acute myeloid leukemia (AML)clinical trialsconcomitant mutationsdriver mutationexportin 1knockout and knock-in phenotypeleukemogenesismeasurable residual disease (MRD)menin inhibitorsNPM1-mutated AMLnuclear–cytoplasmic localizationnucleophosmin (NPM1) generevumenibtreatmentziftomenib

Identifiers

PMID40647396
PMCPMC12248482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.